At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 79 enrolled
Drug / intervention
HB-adMSCs (allogeneic) +1 morebiological
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-blinded, Single-center, Phase 2 Efficacy, and Safety Study of Allogeneic HB-adMSCs for the Treatment of Patients With Chronic Post-COVID-19 Syndrome.
In Brief
A Phase 2 clinical trial evaluating HB-adMSCs (allogeneic) and Placebo for Post COVID-19 Syndrome. Completed, enrolled 79 participants across 1 site.
Detailed Summary
This study will enroll up to 80 subjects with Chronic Post COVID-19 Syndrome. Subjects will receive four intravenous injections of either allogeneic HB-adMSC's or a placebo over 10 weeks with two follow-up visits and an end of study visit at week 26.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPost COVID-19 Syndrome
CountriesUnited States
Collaborators--
Timeline
Phase 2CompletedFinished
20222023202420252026
First PostedNov 2021
Enrollment StartFeb 2022
Primary CompletionApr 2024
TodayJul 2026
First PostedNov 19, 2021
Enrollment StartFeb 2, 2022
Primary CompletionApr 2, 2024
TodayJul 2, 2026
Enrollment to primary: 2.2 yearsPosted 4.6 years ago
Interventions
HB-adMSCs (allogeneic)biological
HB-adMSCs allogenic
Placeboother
Placebo comarator